论文部分内容阅读
目的：观察大剂量重组人白细胞介素Ⅱ（ｒｈＩＬ－２，欧耐特）治疗对恶性肿瘤患者免疫功能的影响。方法：采用ｒｈＩＬ－２×１０６Ｕ，溶于２００ｍｌ生理盐水中，静脉滴注，１次／ｄ，连续５ｄ，停２ｄ，四周为一疗程。所有患者治疗前后均静脉采血进行Ｔ细胞亚群及血清ＴＮＦ－α和ＳＯＤ含量测定。结果：６例未行手术治疗患者，有２例完全反应（ＣＲ）；２１例患者治疗前细胞免疫功能严重障碍，治疗后各项指标均更趋于正常水平。２１例患者共输注治疗４２０次，发生不良反应率仅为８．６％。１４例患者治疗后生活质量明显提高（占６６．７％）。结论：大剂量ｒｈＩＬ－２静脉输注治疗恶性肿瘤对改善免疫功能、控制肿瘤发展和提高生活质量具有明显的功效
Objective: To observe the effect of high-dose recombinant human interleukin II (rhIL-2) on immune function in patients with malignant tumors. Methods: RhIL-2×106U was dissolved in 200ml normal saline and intravenously infused once a day for 5 days and stopped for 2 days. Four weeks was a course of treatment. Blood samples were taken from all patients before and after treatment to measure T cell subsets and serum TNF-α and SOD. RESULTS: In 6 patients without surgery, there were 2 complete responses (CR); 21 patients had severe impaired cellular immune function before treatment, and all indicators were more normal after treatment. Twenty-one patients were treated with 420 infusions and the incidence of adverse reactions was only 8.6%. The quality of life of the 14 patients improved significantly after treatment (66.7%). Conclusion: Intravenous infusion of high-dose rhIL-2 has obvious efficacy in improving immune function, controlling tumor development and improving quality of life.